智通财经获悉，Tevogen Bio(TVGN)周五表示，该公司已扩大与微软(MSFT.US)以人工智能为重点的合作关系，并建立其PredicTcell技术。周一盘前交易中，截至发稿，这家处于临床阶段的专业免疫治疗生物技术公司的股价上涨近38%，至1.86美元。PredicTcell是Tevogen Bio的专利技术，用于预测精确的T细胞靶向。
基于TVGN 489的成功试验结果，Tevogen Bio旨在利用机器学习来执行关键模拟，从而加速新目标的识别。该公司在一份声明中表示，通过利用微软的人工智能，该公司可以更快、更准确地分析整个基因组的大型数据集。Tevogen Bio 也在积极研究人类乳头瘤病毒的潜在治疗方法。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.